Cargando…
Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic
mRNA vaccines have received major attention in the fight against COVID-19. Formulations from companies such as Moderna and BioNTech/Pfizer have allowed us to slowly ease the social distancing measures, mask requirements, and lockdowns that have been prevalent since early 2020. This past year’s focus...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502079/ https://www.ncbi.nlm.nih.gov/pubmed/34637846 http://dx.doi.org/10.1016/j.addr.2021.114000 |
_version_ | 1784580809185820672 |
---|---|
author | Jain, Samagra Venkataraman, Abhijeet Wechsler, Marissa E. Peppas, Nicholas A. |
author_facet | Jain, Samagra Venkataraman, Abhijeet Wechsler, Marissa E. Peppas, Nicholas A. |
author_sort | Jain, Samagra |
collection | PubMed |
description | mRNA vaccines have received major attention in the fight against COVID-19. Formulations from companies such as Moderna and BioNTech/Pfizer have allowed us to slowly ease the social distancing measures, mask requirements, and lockdowns that have been prevalent since early 2020. This past year’s focused work on mRNA vaccines has catapulted this technology to the forefront of public awareness and additional research pursuits, thus leading to new potential for bionanotechnology principles to help drive further innovation using mRNA. In addition to alleviating the burden of COVID-19, mRNA vaccines could potentially provide long-term solutions all over the world for diseases ranging from influenza to AIDS. Herein, we provide a brief commentary based on the history and development of mRNA vaccines in the context of the COVID-19 pandemic. Furthermore, we address current research using the technology and future directions of mRNA vaccine research. |
format | Online Article Text |
id | pubmed-8502079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85020792021-10-12 Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic Jain, Samagra Venkataraman, Abhijeet Wechsler, Marissa E. Peppas, Nicholas A. Adv Drug Deliv Rev Article mRNA vaccines have received major attention in the fight against COVID-19. Formulations from companies such as Moderna and BioNTech/Pfizer have allowed us to slowly ease the social distancing measures, mask requirements, and lockdowns that have been prevalent since early 2020. This past year’s focused work on mRNA vaccines has catapulted this technology to the forefront of public awareness and additional research pursuits, thus leading to new potential for bionanotechnology principles to help drive further innovation using mRNA. In addition to alleviating the burden of COVID-19, mRNA vaccines could potentially provide long-term solutions all over the world for diseases ranging from influenza to AIDS. Herein, we provide a brief commentary based on the history and development of mRNA vaccines in the context of the COVID-19 pandemic. Furthermore, we address current research using the technology and future directions of mRNA vaccine research. Elsevier B.V. 2021-12 2021-10-09 /pmc/articles/PMC8502079/ /pubmed/34637846 http://dx.doi.org/10.1016/j.addr.2021.114000 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Jain, Samagra Venkataraman, Abhijeet Wechsler, Marissa E. Peppas, Nicholas A. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic |
title | Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic |
title_full | Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic |
title_fullStr | Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic |
title_full_unstemmed | Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic |
title_short | Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic |
title_sort | messenger rna-based vaccines: past, present, and future directions in the context of the covid-19 pandemic |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502079/ https://www.ncbi.nlm.nih.gov/pubmed/34637846 http://dx.doi.org/10.1016/j.addr.2021.114000 |
work_keys_str_mv | AT jainsamagra messengerrnabasedvaccinespastpresentandfuturedirectionsinthecontextofthecovid19pandemic AT venkataramanabhijeet messengerrnabasedvaccinespastpresentandfuturedirectionsinthecontextofthecovid19pandemic AT wechslermarissae messengerrnabasedvaccinespastpresentandfuturedirectionsinthecontextofthecovid19pandemic AT peppasnicholasa messengerrnabasedvaccinespastpresentandfuturedirectionsinthecontextofthecovid19pandemic |